BIIB 054

Next Previous
Drug Profile

BIIB 054

Alternative Names: BIIB054

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurimmune Therapeutics
  • Developer Biogen
  • Class Antiparkinsonians; Monoclonal antibodies
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 20 Nov 2017 Biogen completes a phase I trial in Parkinson's disease in USA (IV) (NCT02459886)
  • 17 Nov 2017 Phase-II clinical trials in Parkinson's disease in USA (IV) (NCT03318523)
  • 26 Oct 2017 Biogen plans a phase II trial for Parkinson's Disease in 2017 (NCT03318523)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top